EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients

Jesús Sanz-Sanz iD, Ana Gutiérrez-Casbas iD, Zulema Plaza, Jordi Gratacós iD, Iago Rodríguez-Lago iD, Ignacio Marín-Jiménez, Elisa Trujillo-Martín, Eva Pérez-Pampín iD, Manuel Barreiro-de Acosta iD, María Vanesa Hernández-Hernández iD, Marta Carrillo-Palau iD, María Luz García-Vivar und 9 weitere

Journal of Clinical Medicine · 27.06.2025 · 14 (13) · 4569

DOI: 10.3390/jcm14134569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.06.2025. Verfasst von Jesús Sanz-Sanz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Reumatología, Hospital Universitario Puerta de Hierro, Majadahonda, 28222 Madrid, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen (United Kingdom), Janssen Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The prevalence of inflammatory bowel disease (IBD) in spondyloarthritis (SpA) patients is unknown. Our objective was to assess the prevalence of undiagnosed IBD in SpA patients, including those with axial spondylarthritis (axSpA) or psoriatic arthritis (PsA). Additionally, we examined fecal calprotectin (FC) levels in relation to the accuracy of IBD diagnosis.

Methods

EISER was a cross-sectional, multicenter, observational, rheumatologist–gastroenterologist collaborative study. Patients with SpA naïve to biologics were recruited. Demographic and clinical characteristics, disease activity, and treatment information were collected. Patients with FC ≥ 80 µg/g or IBD-related symptoms underwent a colonoscopy or video capsule endoscopy. Receiver operating characteristic analysis assessed the predictive value of FC for IBD diagnosis.

Results

Of the 570 patients recruited, 494 were evaluable for the main outcome, 248 (50.2%) had axSpA, and 246 (49.8%) had PsA. Overall, 28/494 patients were diagnosed with IBD (5.7%, 95%CI 3.6–7.7). Sorted by clinical entity, 22 (8.9%, 95%CI 5.3–12.4) axSpA and 6 (2.4%, 95%CI 0.5–4.4) PsA patients had a diagnosis of IBD: 24 (86%, 95%CI 79.4–92.6) had ileal/ileocolonic Crohn’s disease (CD), 3 (11%, 95%CI 5.1–16.9) unclassified IBD, and 1 (3.5%, 95%CI 0.0–6.9) ulcerative colitis. The ROC curve for FC and IBD diagnosis (AUC: 0.870, p < 0.001, 95%CI 83.7–89.8) showed that an FC ≥ 147 µg/g had a positive predictive value of 17.4% (95%CI 14.5–20.8)

Conclusions

In SpA, the prevalence of undiagnosed IBD was 5.7%, higher in axSpA (8.9%) than in PsA (2.4%) patients, with CD being the most common. SpA patients with FC levels < 147 µg/g had a very low probability of IBD.

Schlagwörter

Stichwörter der Autor:innen

axial spondylarthritisfecal calprotectininflammatory bowel diseaseprevalence undiagnosticpsoriatic arthritis

Autor:innen und Institutionen

  • Departamento de Reumatología, Hospital Universitario Puerta de Hierro, Majadahonda, 28222 Madrid, Spain.
  • Departamento de Gastroenterología, Hospital General Universitario de Dr. Balmis de Alicante Servicio Digestivo, ISABIAL y CIBERehd, 03010 Alicante, Spain.
  • Unidad de Investigación, Sociedad Española de Reumatología, 28001 Madrid, Spain.
  • Servicio de Reumatología, Parc Taulí, Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.
  • Departamento de Gastroenterología, Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, 48960 Galdakao, Spain.
  • Servicio Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain.

ORCID-Profile: Jesús Sanz-Sanz, Ana Gutiérrez-Casbas, Jordi Gratacós, Iago Rodríguez-Lago, Eva Pérez-Pampín, Manuel Barreiro-de Acosta, María Vanesa Hernández-Hernández, Marta Carrillo-Palau, Maria Lourdes Ladehesa-Pineda, Carolina Merino-Argumánez, Yago González-Lama, Xavier Calvet, Federico Díaz-Gonzalez

Förderung

  • Janssen (United Kingdom)
  • Janssen Pharmaceutical

Zitieren

APA

Sanz-Sanz, J., Gutiérrez-Casbas, A., Plaza, Z., Gratacós, J., Rodríguez-Lago, I., Marín-Jiménez, I., Trujillo-Martín, E., Pérez-Pampín, E., Barreiro-de Acosta, M., Hernández-Hernández, M. V., Carrillo-Palau, M., García-Vivar, M. L., Muñoz-Villafranca, M. C., Ladehesa-Pineda, M. L., Iglesias-Flores, E., Merino-Argumánez, C., González-Lama, Y., Arévalo-Salaet, M., Calvet, X., …, & EISER Collaborative Group (2025). Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients. Journal of Clinical Medicine, 14(13), 4569. https://doi.org/10.3390/jcm14134569

Vancouver

Sanz-Sanz J, Gutiérrez-Casbas A, Plaza Z, Gratacós J, Rodríguez-Lago I, Marín-Jiménez I, et al. Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients. Journal of Clinical Medicine. 2025;14(13):4569. doi:10.3390/jcm14134569

BibTeX
@article{SanzSanz2025,
  author = {Sanz-Sanz, Jesús and Gutiérrez-Casbas, Ana and Plaza, Zulema and Gratacós, Jordi and Rodríguez-Lago, Iago and Marín-Jiménez, Ignacio and Trujillo-Martín, Elisa and Pérez-Pampín, Eva and Barreiro-de Acosta, Manuel and Hernández-Hernández, María Vanesa and Carrillo-Palau, Marta and García-Vivar, María Luz and Muñoz-Villafranca, María Carmen and Ladehesa-Pineda, Maria Lourdes and Iglesias-Flores, Eva and Merino-Argumánez, Carolina and González-Lama, Yago and Arévalo-Salaet, Marta and Calvet, Xavier and Díaz-Gonzalez, Federico and EISER Collaborative Group, EISER Collaborative Group},
  title = {Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {13},
  pages = {4569},
  doi = {10.3390/jcm14134569}
}
Kostenlos starten →